Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 62.00
-0.94 (-1.49%)
At close: Dec 31, 2025
24.87% (1Y)
| Assets | 42.85M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +24.87% |
| Volume | 1,995 |
| Open | 62.75 |
| Previous Close | 62.94 |
| Day's Range | 62.00 - 62.75 |
| 52-Week Low | 38.76 |
| 52-Week High | 64.74 |
| Beta | 1.18 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 24.87% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.74%.
Top 10 Holdings
13.57% of assets| Name | Symbol | Weight |
|---|---|---|
| Amicus Therapeutics, Inc. | FOLD | 1.47% |
| Praxis Precision Medicines, Inc. | PRAX | 1.42% |
| Travere Therapeutics, Inc. | TVTX | 1.38% |
| BioMarin Pharmaceutical Inc. | BMRN | 1.36% |
| Exelixis, Inc. | EXEL | 1.35% |
| Halozyme Therapeutics, Inc. | HALO | 1.34% |
| Rhythm Pharmaceuticals, Inc. | RYTM | 1.31% |
| Regeneron Pharmaceuticals, Inc. | REGN | 1.31% |
| Moderna, Inc. | MRNA | 1.31% |
| Roivant Sciences Ltd. | ROIV | 1.31% |